Increased time spent on discussing testing for colorectal cancer (CRC) was associated with patient satisfaction in older adults. Adults aged 76 to 85 years were more likely to continue testing for ...

Multigene panel testing should be considered for all patients with colorectal cancer (CRC) who are diagnosed younger than age 50 years, new findings suggest. Among 450 patients with early-onset CRC, ...

BALTIMORE, Aug. 27, 2020 /PRNewswire/ -- Sysmex Inostics, Inc., a global leader and pioneer in blood-based circulating tumor DNA (ctDNA) analysis for oncology, today announces the publication of a ...

Please provide your email address to receive an email when new articles are posted on . Annual fecal immunochemical testing was the most effective and cheapest CRC screening method for underserved ...

To kick off the first-ever global colorectal cancer (CRC) awareness report, it is important to note that there were over 1.9 million new cases of colorectal cancer in 2020, making it the third most ...

Please provide your email address to receive an email when new articles are posted on . Increased use of fecal immunochemical testing correlated with more colorectal cancer screenings and early-stage ...

A patient who had repeatedly refused routine screening for colorectal cancer (CRC), despite having lost his 80-year-old father to the disease, was again advised to undergo a colonoscopy at age 56. He ...

Dr Kristen Ciombor discusses utilization of biomarkers and molecular testing in the treatment of patients with CRC. Kristen Ciombor, MD: In terms of molecular testing for colorectal cancer, in early ...

A look at Exact Sciences Corporation’s acquisition by Abbott: review EXAS revenue growth, margins, and CRC/MRD screening ...

A single, upfront genomic test is more effective for detecting Lynch syndrome in colorectal cancer (CRC) patients than the traditional multiple, sequential testing approach, according to new clinical ...

Sysmex Inostics, a subsidiary of Sysmex Corporation, a global leader in blood based circulating tumor DNA (ctDNA) analysis and molecular diagnostics for oncology is pleased to highlight an expert ...

Oxford, UK - 5 February 2025 - Oxford BioDynamics, Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests based on the EpiSwitch® 3D genomics platform, announces the ...